Toxicology Clinical Trials This is an OPML file. It can be used to export all the MedWorm RSS feeds on this topic into your personal RSS reader (usually you have to save this file to your own computer before clicking on an Import OPML command in your own feed reader to upload the file which will then import all the feeds) or it can be used by webmasters to integrate MedWorm feeds with their own website. This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the most recent publications within this specialty of the MedWorm directory.

Plasma Citrulline: A Marker for Monitoring & Quantifying Radiation-Induced Small Bowel Toxicity
Condition: Radiation-induced Small Bowel Toxicity.Intervention: Biological: Plasma citrullineSponsors: Asan Medical Center; Asan Medical CenterRecruiting - verified May 2013 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 28, 2013 Category: Research Source Type: clinical trials

Assessing Patient Comfort With Two Different Multi-Purpose Disinfecting Solutions
Condition: Contact Lens Solution ToxicityInterventions: Other: RevitaLens; Other: OptiFree PureMoistSponsors: Hom, Milton M., OD, FAAO; Hom, Milton M., OD, FAAO; Abbott Medical OpticsEnrolling by invitation - verified May 2013 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 24, 2013 Category: Research Source Type: clinical trials

J Neurooncol. 2013 Apr 6. [Epub ahead of print] Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma. Santoni M, Scoccianti S, Lolli I, Fabrini MG, Silvano G, Detti B, Perrone F, Savio G, Iacovelli R, Burattini L, Berardi R, Cascinu S. Clinica di Oncologia Medica, AOU "Ospedali Riuniti", Università Politecnica delle Marche, via Tronto 10/A, 60100, Ancona, Italy, mattymo@alice.it. Abstract Fotemustine (FTM) is a common treatment option for glioblastoma patients refractory to temozolomide (TMZ). Although elderly patients represent a large component of glioblastoma population, the feasibility and the efficacy of second-line FTM are not available in those patients.We retrospectively analyzed the records of glioblastoma patients older than 65 years, receiving FTM at a dose of 70-100 mg/m2 of FTM every week for 3 consecutive weeks (induction phase) and then every 3 weeks (70-100 mg/m2), as second-line treatment.Between January 2004 and December 2011, 65 glioblastoma patients (median age, 70 years; range, 65-79 years) were eligible for this analysis. Sixty-five patients received a total of 364 FTM cycles, with a median of 4 cycles for each patient. After induction, we observed 1 complete response (1.5 %), 12 partial responses (18.5 %), 18 stable diseases (27.7 %), and 34 patients` progressions (47.7 %). Disease control rate was 43.1 %. Median survival from the beginning of FTM therapy was 7.1 months, while the median progression-free survival was 4.2 months, and the 6-months progression free survival rate was 35.4 %. The most relevant grade 3-4 toxicity events were thrombocytopenia (15.3 %) and neutropenia (9.2 %). In the univariate and multivariate analysis, time from radiotherapy to FTM, number of TMZ and FTM cycles and disease control resulted independent prognostic factors.This study showed that FTM is a valuable therapeutic option for elderly glioblastoma patients, with a safe toxicity profile. PMID: 23564276 [PubMed - as supplied by publisher]
(Source: Clinical Trials And Noteworthy Treatments For Brain Tumors)
Source: Clinical Trials And Noteworthy Treatments For Brain Tumors - April 13, 2013 Category: Cancer & Oncology Source Type: clinical trials

Data Demonstrating the Safety and Efficacy of Chimerix's Antiviral CMX001 Presented at BMT Tandem Meetings
- No evidence of CMX001-associated kidney toxicity was seen in stem cell transplant recipients who were enrolled in a 230-patient Phase 2 study to evaluate CMX001 for prevention of cytomegalovirus (CMV) infection. Subjects on CMX001 had stable to... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 25, 2013 Category: Pharmaceuticals Source Type: clinical trials

Effect of Bovine Colostrum on Toxicity and Inflammatory Responses
Condition: Acute Lymphoblastic LeukemiaInterventions: Dietary Supplement: Bovine Colostrum; Dietary Supplement: placeboSponsors: Odense University Hospital; Steffen Husby; University of Southern Denmark; Rigshospitalet, DenmarkNot yet recruiting - verified January 2013 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2013 Category: Research Source Type: clinical trials

Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis.
(Source: Clinical Trials And Noteworthy Treatments For Brain Tumors)
Source: Clinical Trials And Noteworthy Treatments For Brain Tumors - January 7, 2013 Category: Cancer & Oncology Source Type: clinical trials